Comparing the effects of low-dose tirzepatide (2.5 mg vs 5 mg) for obesity in non-diabetic Japanese adults

Data comparing the efficacy of 2.5 mg and 5 mg tirzepatide in non-diabetic adults with obesity are limited.

• Tirzepatide may lead to significant weight reduction in individuals with obesity.
• The safety profiles of the two dosages are not fully established due to limited data.
• Combining tirzepatide with lifestyle intervention could enhance weight loss outcomes.

Simplified